SHORT-TERM COMPUTER-ASSISTED QUANTIFICATION OF PLUS DISEASE AFTER TREATMENT OF TYPE 1 RETINOPATHY OF PREMATURITY WITH INTRAVITREAL BEVACIZUMAB OR RETINAL LASER PHOTOCOAGULATION. Issue Volume 15:Issues 3(2021) (May 2021)

• Record Type: Journal Article
• Authors: Cabrera, Michelle T.; Chia, Thomas; Wallace, David K.; Ulrich, J. Niklas; Freedman, Sharon F.; Ding, Leona; Gertsch, Kevin R.
• Is Part Of: Retinal cases & brief reports. Volume 15:Issues 3(2021)
• Publication Date: 2021-05
• Subjects: bevacizumab -- retinopathy of prematurity -- type 1 retinopathy of prematurity -- ROPtool -- plus disease -- laser -- RetCam; Retina -- Diseases -- Periodicals; Retina -- Periodicals; Retinal Diseases -- Periodicals; Retina -- Case Reports; Retinal Diseases -- Case Reports; 617.7
• DOI: 10.1097/ICB.0000000000000794
• Languages: English
• ISSNs: 1935-1089

Abstract

Abstract : Purpose: To compare objectively measured changes in plus disease after bevacizumab and laser for Type 1 retinopathy of prematurity. Methods: ROPtool (a computer program) analyzed fundus images at baseline, 1 week, and subsequent examinations. Results: Six infants (9 eyes) were treated with bevacizumab and 7 (12 eyes) with laser. One week after treatment, bevacizumab compared with laser resulted in a greater median percent change from pretreatment in tortuosity (−53.8 vs. −0.2%, P < 0.001) and overall plus disease (−20.1 vs. −3.1%, P < 0.001). Change in dilation did not differ (−3.5 vs. −5.5%, P = 0.48). After week 1, all median ROPtool parameters continued to decrease for both groups. At last follow-up (median 3, range: 2–10 weeks), both bevacizumab and laser significantly decreased tortuosity (−54.3 and −23.8%), dilation (−8.7 and −7.5%), and overall plus disease (−27.3 and −10.3%). Conclusion: Improvement in plus disease, in particular tortuosity, likely occurs more quickly after bevacizumab compared with laser, particularly at 1 week after treatment. These results guide clinical expectations for plus disease resolution after both treatment modalities. Abstract : Based on computer-assisted analysis of fundus photographs (ROPtool), plus disease, in particular tortuosity relative to dilation, significantly improved in 1 week after intravitreal bevacizumab injection for Type 1 retinopathy of prematurity compared with retinal laser photocoagulation. After Week 1, plus disease continued to improve in both treatment groups.